Skip to main content
. 2022 Jul 28;13:944183. doi: 10.3389/fimmu.2022.944183

Figure 3.

Figure 3

Potential of host-directed therapies (HDTs) to improve BCG efficacy. Diverse HDTs aiming at distinct pathways are under evaluation to improve clinical outcomes. HDTs restrict pathogen-induced subversion strategies to ameliorate host defenses against M.tb.